Do Interference-Based Cut-Points Differentiate Mild, Moderate, and Severe Levels of 16 Cancer-Related Symptoms Over Time?
Do Interference-Based Cut-Points Differentiate Mild, Moderate, and Severe Levels of 16 Cancer-Related Symptoms Over Time?
复制标题
DOI：
10.1016/j.jpainsymman.2008.01.010
复制
发表时间：
2009-02-01
影响因子：
4.7
通讯作者：
Given, Barbara
中科院分区：
文献类型：
--
作者：
Jeon, Sangchoon;Given, Charles W.;Given, Barbara
在我们之前的工作中，我们建立了基于干扰的切点，以区分接受化疗的癌症患者报告的16种症状的中度和轻度，以及严重和中度水平。这项工作考察了这种差异随着时间的推移是如何一致的。如果严重程度随着时间的推移成功区分干扰得分，则可以开发基于锚的类别来评估患者对干预的反应。为了检验干扰分数在三个严重程度类别上的差异，使用了两个症状管理试验的数据。599名患者在8周内发生的6次接触中的每一次都被询问了从0(不存在)到10的16种症状中每一种的严重程度，以及每种症状对生活乐趣、与他人的关系、一般日常活动和情绪的干扰程度。使用了将干扰分数与症状严重程度相关联的纵向模型。在每一次接触中测试轻度、中度和重度调整后的平均干扰分数之间的差异。基于干扰的严重程度类别之间的差异随着时间的推移是一致的，并且具有临床重要性，因此可以用于锚定症状严重程度的变化。J疼痛症状管理2009；37：220-232。(C)2009年美国癌症疼痛缓解委员会。爱思唯尔公司出版，版权所有。
In our previous work, we established interference-based cutpoints to differentiate moderate from mild, and severe from moderate levels of severity for 16 symptoms as reported by cancer patients undergoing chemotherapy. This work examines how consistent the differentiation is over time. If the levels of severity successfully differentiate interference scores over time, then anchor-based categories can be developed to evaluate patients' responses to the intervention. To test the differentiation of the interference scores by the three severity categories, data from two symptom management trials were used. Five hundred and ninety-nine patients were queried at each of the six contacts that occurred over eight weeks as to the severity of each of the 16 symptoms on the scale from 0 (not present) to 10 and the extent to which each symptom interfered with enjoyment of life, relationships with others, general daily activities and emotions. Longitudinal models that related interference scores to severity levels of symptoms were used. Differences among adjusted mean interference scores for mild, moderate, and severe levels were tested at each contact. Differences among interference-based severity categories were consistent over time and clinically important, and thus can be used to anchor changes in symptom severity. J Pain Symptom Manage 2009;37:220-232. (c) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.